Celltrion Healthcare, Celltrion Group’s overseas sales unit, announced Tuesday that Vegzelma, Celltrion’s biosimilar referencing Roche's Avastin (bevacizumab), has been listed as a preferred drug on a formulary managed by Ventegra. “Through Ventegra's proprietary formulary program, which covers 13 million members in the US, Vegzelma will be able to increase its share in the US bevacizumab ...

Related Keywords

Tom Nusbickel , Roche Avastin , Robertt Taketomo , Celltrion Group , Celltrion Healthcare , United States , Celltrion United States , The Korea Herald , Orean News , Oreaherald , Outh Korea News , Outh Korea News In English , Sia News , K Pop , Pop , 더코리아헤럴드 , 코리아 헤럴드 ,